Recently, it was found that eIF5A2 promotes doxorubicin resistance of colon cancer cells by regulating EMT, suggesting that inhibition of eIF5A2 can be used as a way to reverse the drug resistance of colorectal cancer (Figure 9) (Bao et al., 2015). Here, EIF5A2 is linked to malignant colon neoplasm.